Suppr超能文献

COBAS INTEGRA 400上的治疗药物监测——评估结果

Therapeutic drug monitoring on COBAS INTEGRA 400--evaluation results.

作者信息

Domke I, Cremer P, Huchtemann M

机构信息

Roche Diagnostics GmbH, Mannheim, Germany.

出版信息

Clin Lab. 2000;46(9-10):509-15.

Abstract

The COBAS INTEGRA 400 (Roche Diagnostics GmbH) is a random access analyzer with a consolidated test menue for routine clinical chemistry, specific proteins, drugs of abuse screening and therapeutic drug monitoring (TDM) and different measuring technologies. It was the aim of the present study to evaluate the suitability of this instrument as dedicated analyzer for TDM. Eight assays based on three different technologies were included: Acetaminophen (enzymatic method), Amikacin/ Phenytoin/ Free Phenytoin/ Lidocaine (fluorescence polarization immunoassays; FPIA), Digitoxin/Digoxin (kinetic interaction of microparticles in solution; KIMS). The study comprised the determination of imprecision according to NCCLS EP-T protocol, method comparison and linearity studies. The assays were compared with the corresponding methods on AxSYM or TDx analyzers (Abbott Laboratories). For Acetaminophen and Amikacin COBAS INTEGRA 700 was used as additional comparison instrument. The results are summarized in a table (table 6). Precision results are well acceptable with within-run CVs < 5% and total CVs < 6% except for Digitoxin and Digoxin which show a somewhat higher imprecision at low concentrations. Results obtained for Acetaminophen and Amikacin on COBAS INTEGRA 400 and 700 show excellent agreement. A good comparability is also found between COBAS INTEGRA 400 and AxSYM or TDx methods with slight systematic deviations for Acetaminophen, Amikacin and Free Phenytoin. The lower correlation coefficient for the digoxin method comparison can be attributed to two discrepant samples. Linearity throughout the range studied which covered > 80% of the measuring range was confirmed for the five assays tested (Digitoxin, Digoxin, Lidocaine, Free Phenytoin, Phenytoin) based on the acceptance criteria of +/- 10% deviation of the measured values from the theoretical values. Based on the analytical performance of the TDM tests studied it can be concluded that the COBAS INTEGRA 400 is very well suited for routine TDM analysis.

摘要

COBAS INTEGRA 400(罗氏诊断有限公司)是一款随机存取分析仪,具备用于常规临床化学、特定蛋白质、药物滥用筛查及治疗药物监测(TDM)的综合测试菜单以及不同的测量技术。本研究的目的是评估该仪器作为专用TDM分析仪的适用性。纳入了基于三种不同技术的八项检测:对乙酰氨基酚(酶法)、阿米卡星/苯妥英/游离苯妥英/利多卡因(荧光偏振免疫分析法;FPIA)、洋地黄毒苷/地高辛(溶液中微粒的动力学相互作用;KIMS)。该研究包括根据NCCLS EP-T方案测定不精密度、方法比较和线性研究。将这些检测与AxSYM或TDx分析仪(雅培实验室)上的相应方法进行比较。对于对乙酰氨基酚和阿米卡星,使用COBAS INTEGRA 700作为额外的比较仪器。结果汇总在一张表格中(表6)。除洋地黄毒苷和地高辛在低浓度时显示出稍高的不精密度外,批内CV<5%且总CV<6%时,精密度结果完全可以接受。在COBAS INTEGRA 400和700上获得的对乙酰氨基酚和阿米卡星的结果显示出极好的一致性。在COBAS INTEGRA 400与AxSYM或TDx方法之间也发现了良好的可比性,对乙酰氨基酚、阿米卡星和游离苯妥英存在轻微的系统偏差。地高辛方法比较中较低的相关系数可归因于两个有差异的样本。根据测量值与理论值偏差±10%的接受标准,在所测试的五项检测(洋地黄毒苷、地高辛、利多卡因、游离苯妥英、苯妥英)中,在所研究的涵盖>80%测量范围的整个范围内均确认了线性。基于所研究的TDM检测的分析性能,可以得出结论,COBAS INTEGRA 400非常适合常规TDM分析。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验